<DOC>
	<DOCNO>NCT00438854</DOCNO>
	<brief_summary>The purpose research study see Dasatinib effective safe give people relapse chronic lymphocytic leukemia ( CLL ) determine effect drug LYN kinase activity blood bone marrow . Recent research show key enzyme CLL cell responsible cell survival . This enzyme call LYN kinase . Laboratory study show inhibition LYN kinase CLL cell result death CLL cell . Dasatinib ability inhibit LYN kinase , therefore , effect CLL cell .</brief_summary>
	<brief_title>Dasatinib Relapsed Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>- After screen procedure confirm participant eligible willing participate research study , follow test procedure . - Dasatinib give orally daily . Each participant pill diary record dos miss dos . All necessary drug refill give clinic appointment , time pill diary unused study drug return . - During first month study treatment participant come clinic follow interval : Day 1 : An EKG perform two hour first dose medication ; Days 3-8 : Blood sample draw day 3-8 ; Weeks 2-4 : A physical examination , EKG blood sample draw week . - Beginning second month study treatment , participant come clinic monthly two year . The following test procedures do ; physical examination ( monthly ) , blood work ( monthly ) , pregnancy test ( monthly ) , EKG ( monthly 6 month , medically indicate ) , CT neck , chest abdomen ( every 2 month 6 month , every 6 month ) , end month 2 , additional blood drawn research test . - Participants continue take study drug two year long disease progress experience serious side effect .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>18 year age old CLL/SLL cell positive flow cytometry ( immunostaining ) CD19 , CD23 CD . Patients may CD23 negative long also cyclin D1 negative . Must fail least 1 prior fludarabine contain regimen fail least 2 nonfludarabine contain regimen contraindication fludarabine use ECOG performance status 2 good Adequate organ function tolerate chemotherapy Adequate method contraception Pregnant breastfeed woman Uncontrolled angina within 3 month Diagnosed suspected congenital long QT syndrome History clinically significant ventricular arrhythmia Prolonged QTc interval preentry electrocardiogram Uncontrolled hypertension Drugs generally accept risk cause Torsades de Pointes Patient know HIV positive Known significant bleeding disorder unrelated CLL Drugs interfere platelet function coagulation must stop least 7 day prior entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>dasatinib</keyword>
	<keyword>BMS-354825</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>LYN kinase</keyword>
</DOC>